Edition:
United States

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

155.07USD
10:17am EDT
Change (% chg)

$0.06 (+0.04%)
Prev Close
$155.01
Open
$155.01
Day's High
$155.37
Day's Low
$154.75
Volume
318,793
Avg. Vol
3,626,932
52-wk High
$184.21
52-wk Low
$133.64

AMGN.O

Chart for AMGN.O

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.36
Market Cap(Mil.): $113,994.20
Shares Outstanding(Mil.): 735.40
Dividend: 1.15
Yield (%): 2.97

Financials

  AMGN.O Industry Sector
P/E (TTM): 14.69 142.43 17.21
EPS (TTM): 10.55 -- --
ROI: 11.79 -8.96 -4.95
ROE: 26.61 -11.79 -4.17

BRIEF-Feldan Therapeutics and Elasmogen announce research agreement with Amgen

* Feldan Therapeutics and Elasmogen announce research agreement with Amgen to develop intracellular biologics

May 09 2017

BRIEF-Amgen files for potential five-part senior notes offering

* Amgen inc files for potential five-part senior notes offering - sec filing Source text for Eikon: (http://bit.ly/2qh9EEe) Further company coverage:

May 08 2017

BRIEF-Amgen, Harvard Pilgrim agree to contract for repatha

* Amgen and Harvard Pilgrim agree to first cardiovascular outcomes-based refund contract for repatha (evolocumab)

May 02 2017

India watchdog orders antitrust probe into Roche cancer drug

MUMBAI India's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients.

Apr 27 2017

UPDATE 1-India watchdog orders antitrust probe into Roche cancer drug

MUMBAI, April 27 India's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients.

Apr 27 2017

Cost controls help offset lower Amgen first-quarter drug sales

Amgen Inc on Wednesday reported higher-than-expected first-quarter profit as cost controls helped offset a sharp drop in sales of Enbrel, its blockbuster rheumatoid arthritis and psoriasis drug.

Apr 26 2017

BRIEF-Amgen reports Q1 GAAP earnings per share $2.79

* Says 2017 earnings per share guidance increased to $10.64-$11.32 on GAAP basis, and $12.00-$12.60 on non-GAAP basis

Apr 26 2017

UPDATE 3-Cost controls help offset lower Amgen 1st-quarter drug sales

April 26 Amgen Inc on Wednesday reported higher-than-expected first-quarter profit as cost controls helped offset a sharp drop in sales of Enbrel, its blockbuster rheumatoid arthritis and psoriasis drug.

Apr 26 2017

BRIEF-Amgen optimistic for Enbrel sales rebound

* Amgen says optimistic about rebound in Enbrel sales in coming quarters after Q1 decline

Apr 26 2017

Amgen first-quarter profit exceeds Street estimates on lower costs

April 26 Amgen Inc on Wednesday reported higher-than-expected first-quarter profit as cost controls helped offset a sharp drop in sales of Enbrel, its blockbuster rheumatoid arthritis and psoriasis drug.

Apr 26 2017

More From Around the Web

Earnings vs. Estimates